- Home
- BLRX vs SNGX Comparison
BLRX vs SNGX Comparison
Compare BLRX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- SNGX
- Stock Information
- Founded
- BLRX 2003
- SNGX 1987
- Country
- BLRX Israel
- SNGX United States
- Employees
- BLRX N/A
- SNGX N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- SNGX Health Care
- Exchange
- BLRX Nasdaq
- SNGX Nasdaq
- Market Cap
- BLRX 17.1M
- SNGX 13.8M
- IPO Year
- BLRX 2011
- SNGX 1987
- Fundamental
- Price
- BLRX $3.47
- SNGX $1.55
- Analyst Decision
- BLRX Strong Buy
- SNGX Strong Buy
- Analyst Count
- BLRX 2
- SNGX 1
- Target Price
- BLRX $19.00
- SNGX $6.00
- AVG Volume (30 Days)
- BLRX 29.9K
- SNGX 1.7M
- Earning Date
- BLRX 11-24-2025
- SNGX 11-10-2025
- Dividend Yield
- BLRX N/A
- SNGX N/A
- EPS Growth
- BLRX N/A
- SNGX N/A
- EPS
- BLRX N/A
- SNGX N/A
- Revenue
- BLRX $17,251,000.00
- SNGX N/A
- Revenue This Year
- BLRX N/A
- SNGX N/A
- Revenue Next Year
- BLRX N/A
- SNGX N/A
- P/E Ratio
- BLRX N/A
- SNGX N/A
- Revenue Growth
- BLRX 1.19
- SNGX N/A
- 52 Week Low
- BLRX $2.30
- SNGX $1.09
- 52 Week High
- BLRX $22.60
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- BLRX 37.37
- SNGX 41.58
- Support Level
- BLRX $3.51
- SNGX $1.54
- Resistance Level
- BLRX $3.89
- SNGX $1.61
- Average True Range (ATR)
- BLRX 0.22
- SNGX 0.09
- MACD
- BLRX -0.05
- SNGX 0.03
- Stochastic Oscillator
- BLRX 17.85
- SNGX 22.22
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).